Miller S, Crystal E, Garfinkle M, Lau C, Lashevsky I, Connolly S J
Arrhythmia Services, Schulich Heart Centre, Department of Medicine, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Heart. 2005 May;91(5):618-23. doi: 10.1136/hrt.2004.033811.
To assess the efficacy of the administration of magnesium as a method for the prevention of postoperative atrial fibrillation (AF) and to evaluate its influence on hospital length of stay (LOS) and mortality.
Literature search and meta-analysis of the randomised control studies published since 1966.
20 randomised trials were identified, enrolling a total of 2490 patients. Study sample size varied between 20 and 400 patients. Magnesium administration decreased the proportion of patients developing postoperative AF from 28% in the control group to 18% in the treatment group (odds ratio 0.54, 95% confidence interval (CI) 0.38 to 0.75). Data on LOS were available from seven trials (1227 patients). Magnesium did not significantly affect LOS (weighted mean difference -0.07 days of stay, 95% CI -0.66 to 0.53). The overall mortality was low (0.7%) and was not affected by magnesium administration (odds ratio 1.22, 95% CI 0.39 to 3.77).
Magnesium administration is an effective prophylactic measure for the prevention of postoperative AF. It does not significantly alter LOS or in-hospital mortality.
评估镁剂预防术后房颤(AF)的疗效,并评价其对住院时间(LOS)和死亡率的影响。
对1966年以来发表的随机对照研究进行文献检索和荟萃分析。
共纳入20项随机试验,总计2490例患者。研究样本量在20至400例患者之间。使用镁剂使术后发生房颤的患者比例从对照组的28%降至治疗组的18%(比值比0.54,95%置信区间(CI)0.38至0.75)。七项试验(1227例患者)提供了住院时间的数据。镁剂对住院时间无显著影响(加权平均住院天数差异为-0.07天,95%CI -0.66至0.53)。总体死亡率较低(0.7%),且不受镁剂使用的影响(比值比1.22,95%CI 0.39至3.77)。
使用镁剂是预防术后房颤的有效预防措施。它不会显著改变住院时间或院内死亡率。